JP2016199578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016199578A5 JP2016199578A5 JP2016135208A JP2016135208A JP2016199578A5 JP 2016199578 A5 JP2016199578 A5 JP 2016199578A5 JP 2016135208 A JP2016135208 A JP 2016135208A JP 2016135208 A JP2016135208 A JP 2016135208A JP 2016199578 A5 JP2016199578 A5 JP 2016199578A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- subject
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000024891 symptom Diseases 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000001613 Gambling Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 206010021567 Impulsive behaviour Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 1
- 206010060891 General symptom Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 231100000870 cognitive problem Toxicity 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- RNRYULFRLCBRQS-UHFFFAOYSA-N O=C(CN1CCC(CN(Cc2ccccc22)C2=O)CC1)c(cc1)ccc1F Chemical compound O=C(CN1CCC(CN(Cc2ccccc22)C2=O)CC1)c(cc1)ccc1F RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 | |
| US61/366,080 | 2010-07-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520841A Division JP2013531073A (ja) | 2010-07-20 | 2011-07-20 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225061A Division JP6419294B2 (ja) | 2010-07-20 | 2017-11-22 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016199578A JP2016199578A (ja) | 2016-12-01 |
| JP2016199578A5 true JP2016199578A5 (enExample) | 2017-03-02 |
Family
ID=45497167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520841A Pending JP2013531073A (ja) | 2010-07-20 | 2011-07-20 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2016135208A Pending JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2017225061A Active JP6419294B2 (ja) | 2010-07-20 | 2017-11-22 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520841A Pending JP2013531073A (ja) | 2010-07-20 | 2011-07-20 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225061A Active JP6419294B2 (ja) | 2010-07-20 | 2017-11-22 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20130274290A1 (enExample) |
| EP (2) | EP2595485B1 (enExample) |
| JP (3) | JP2013531073A (enExample) |
| KR (1) | KR101867634B1 (enExample) |
| CN (2) | CN103108548A (enExample) |
| BR (1) | BR112013001302A2 (enExample) |
| CA (2) | CA3154027A1 (enExample) |
| DK (1) | DK2595485T3 (enExample) |
| ES (1) | ES2914120T3 (enExample) |
| HU (1) | HUE058736T2 (enExample) |
| PL (1) | PL2595485T3 (enExample) |
| PT (1) | PT2595485T (enExample) |
| RU (2) | RU2613201C2 (enExample) |
| TW (1) | TWI520949B (enExample) |
| WO (1) | WO2012012543A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| JP2018501217A (ja) * | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| CN113694065A (zh) * | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| CA3067031A1 (en) | 2017-06-21 | 2018-12-27 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| MA53437A (fr) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences Inc | Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection |
| WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ235841A (en) * | 1989-10-27 | 1993-03-26 | Du Pont | (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions |
| KR927002347A (ko) * | 1989-10-27 | 1992-09-03 | 레이몬드 지. 아너 | (n-프탈이미도알킬) 피페리딘 |
| EP0637306B1 (en) * | 1992-04-23 | 2001-05-30 | Merrell Pharmaceuticals Inc. | 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy |
| IL151533A0 (en) * | 2000-02-29 | 2003-04-10 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en not_active Ceased
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active Active
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en not_active Abandoned
-
2025
- 2025-01-15 US US19/021,774 patent/US20250228838A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018065829A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2018021046A5 (enExample) | ||
| JP2018529742A5 (enExample) | ||
| JP2006104221A5 (enExample) | ||
| JP2017531033A5 (enExample) | ||
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| JP2016014070A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2015511609A5 (enExample) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2015510916A5 (enExample) | ||
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2020529995A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016512817A5 (enExample) | ||
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| JP2017533220A5 (enExample) | ||
| JP2013531073A5 (enExample) | ||
| MX393863B (es) | Metodo para preparar compuesto derivado heterociclico, composicion que contiene el mismo compuesto, e hidrato del mismo compuesto. | |
| JP2018505218A5 (enExample) | ||
| CN103356620A (zh) | 双苄基异喹啉类化合物或其在药学上可接受的盐治疗和改善抑郁症状的新用途 | |
| JP2016522188A5 (enExample) |